ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigation of the Immuno-regulation and Viral Hepatitis Among Patients With or After Dengue Fever Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00688389
Recruitment Status : Recruiting
First Posted : June 2, 2008
Last Update Posted : March 8, 2018
Sponsor:
Collaborator:
Centers for Disease Control and Prevention
Information provided by (Responsible Party):
Kaohsiung Medical University Chung-Ho Memorial Hospital

Study Description
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The study will collect the blood samples from 350 healthy persons and 350 persons infected with dengue fever.

Condition or disease Intervention/treatment
Dengue Fever Other: case/control

Detailed Description:
Research has showed that CLEC5A interacts with dengue virion directly, and is responsible for dengue virus (DV)-induced DAP12 phosphorylation. Data suggests that CLEC5A is a potential therapeutic target for dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS). This project will study the genes of CLEC5A, Mannose receptor, DC-SIGN, NALP, decoy receptor 3 (DcR3), Toll-like receptors(TLRs), and (Nod)-like receptors (NLRs) for both DF and DHF groups. In addition, serum level of decoy receptor 3 (DcR3) will be tested. The study will collect the blood samples from 350 healthy persons and 350 persons infected with dengue fever.

Study Design
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Observational
Estimated Enrollment : 700 participants
Observational Model: Case-Control
Time Perspective: Other
Official Title: Follow-up the Health Condition , Investigation of the Immuno-regulation , and the Study for Interaction of Viral Hepatitis--- Among Patients With or After Dengue Fever Infection
Study Start Date : July 2007
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dengue Fever Hepatitis
U.S. FDA Resources

Groups and Cohorts
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
healthy Other: case/control
case: infected dengue fever people control:healthy people
DF Other: case/control
case: infected dengue fever people control:healthy people
DHF Other: case/control
case: infected dengue fever people control:healthy people


Outcome Measures
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. 檢查肝臟、腎臟及其他生化功能，並分析宿主免疫調控及血小板變化機致 [ Time Frame: 2007/7/1 ]
    抽血20 c.c 檢查肝臟、腎臟及其他生化功能，並分析宿主免疫調控及血小板變化機致


Biospecimen Retention:   Samples With DNA
blood samples

Eligibility Criteria
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
The samples are obtained from the Kaohsiung Medical University Chung-Ho Memorial Hospital in Kaohsiung, Taiwan.
Criteria

Inclusion Criteria:

  • Clinical diagnosis of Dengue fever

Exclusion Criteria:

Contacts and Locations
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00688389


Contacts
Contact: Jih-Jin Tsai, MD 886-7-312-1101 ext 5677 jijits@cc.kmu.edu.tw

Locations
Taiwan
Kaoshing Medical University Chung-Ho Memorial Hospital Recruiting
Kaohsiung, Taiwan
Contact: Jih-Jin Tsai, MD    886-7-312-1101 ext 5677    jijits@cc.kmu.edu.tw   
Sponsors and Collaborators
Kaohsiung Medical University Chung-Ho Memorial Hospital
Centers for Disease Control and Prevention
More Information
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: Kaohsiung Medical University Chung-Ho Memorial Hospital
ClinicalTrials.gov Identifier: NCT00688389     History of Changes
Other Study ID Numbers: KMUH-IRB-960195_1
CB9615
First Posted: June 2, 2008    Key Record Dates
Last Update Posted: March 8, 2018
Last Verified: May 2017

Keywords provided by Kaohsiung Medical University Chung-Ho Memorial Hospital:
Dengue fever, CLEC5A, Mannose receptor, DC-SIGN, NALP,
decoy receptor 3 (DcR3), Toll-like receptors(TLRs),
(Nod)-like receptors (NLRs)

Additional relevant MeSH terms:
Fever
Dengue
Body Temperature Changes
Signs and Symptoms
Arbovirus Infections
 Virus Diseases
Flavivirus Infections
Flaviviridae Infections
RNA Virus Infections
Hemorrhagic Fevers, Viral